Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherap
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
| Condition(s) | Oligometastatic Prostate Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging. |
| Who can participate | Inclusion Criteria: 1. Male aged 18 years or older at screening 2. Patient has provided written informed consent 3. Histologically confirmed prostate adenocarcinoma w 4. Prior definitive treatment of the primary with either curative intent radiotherapy and/or surgery 5. Patient has 1-5 sites of nodal or bony metastases on 68Ga-PSMA or 18F-DCFPyL PET/CT 6. Adequate haematological function as defined by: * Absolute neutrophil count (ANC) ≥1.5 x 109/L * Platelet count \>150x 109/L * Haemoglobin ≥100 g/L * Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula) 7. Assessed as suitable for SABR by a radiation oncologist 8. Patients must agree to use an adequate method of contraception 9. Have a performance status of 0-1 on the ECOG Performance Scale Exclusion Criteria: 1. Prior systemic thera |
| Ages | 18 Years |
| Sex | Male |
| Lead sponsor | Peter MacCallum Cancer Centre, Australia |
| Locations | St Leonards, New South Wales, Australia; Melbourne, Victoria, Australia; Tel Aviv, Israel |
| Start date | 2023-12-14 |
| NCT ID | NCT05560659 |
| Official listing | https://clinicaltrials.gov/study/NCT05560659 |